文献速递临床试验与 GCP

MAPLE-PD试验:胰十二指肠切除术中肠系膜入路与常规入路治疗胰腺癌的多中心随机对照试验方案

MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
PubMed 文献 · Trials · 2018-11-08

MAPLE-PD是一项日本多中心随机对照试验,计划纳入354例拟行胰十二指肠切除术的胰腺导管腺癌患者,术前随机分为常规入路(A组)或肠系膜入路(B组)。主要终点为意向性治疗分析的总生存期,次要终点包括术中出血量、R0切除率和无复发生存期。

要点

  • 肠系膜入路以肠系膜上动脉周围组织清扫开始,旨在早期判断可切除性并减少出血。
  • 试验计划从15家日本高容量中心随机纳入354例胰腺导管腺癌患者。
  • 主要终点为意向性治疗分析的总生存期,次要终点包括出血量、R0率和无复发生存期。

核心结论

  • 若MAPLE-PD试验证实肠系膜入路对胰腺导管腺癌患者具有肿瘤学获益,该入路可能成为胰十二指肠切除术的标准入路。

研究设计与样本

  • 日本多中心随机对照试验,计划从15家高容量中心随机纳入354例拟行胰十二指肠切除术的胰腺导管腺癌患者。
  • 患者术前随机分为常规入路(A组)或肠系膜入路(B组)。

关键数值与推荐

  • A组手术以Kocher maneuver开始,在切除步骤最后解剖肠系膜上动脉周围结缔组织。
  • B组手术以解剖肠系膜上动脉周围结缔组织开始,以Kocher maneuver结束。
  • 主要终点为意向性治疗分析的总生存期,次要终点包括术中出血量、R0率和无复发生存期。

临床怎么用

  • 该试验尚在进行中,其结果将为胰十二指肠切除术中肠系膜入路能否改善胰腺导管腺癌患者生存提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mesenteric approach is an artery-first approach to pancreaticoduodenectomy for pancreatic cancer, which starts with the dissection of connective tissues around the superior mesenteric artery. The procedure aims for early confirmation of resectability by checking the surgical margin around the superior mesenteric artery first during the operation. It also aims to decrease intraoperative blood loss by early ligation of the inferior pancreaticoduodenal artery and to increase R0 rate by complete clearance of the lymph nodes around the superior mesenteric artery and pancreatic head plexus II, the most favorable positive margin site for pancreatic ductal adenocarcinoma. Furthermore, it aims to avoid the spread of cancer cells during operation (nontouch isolation technique). The MAPLE-PD (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy) trial investigates whether the mesenteric approach can prolong the survival of patients with pancreatic ductal adenocarcinoma who undergo pancreaticoduodenectomy compared with the conventional approach. METHODS/DESIGN: The MAPLE-PD trial is a Japanese multicenter randomized controlled trial that compares the surgical outcomes between the mesenteric and conventional approaches to pancreaticoduodenectomy. Patients with pancreatic ductal adenocarcinoma scheduled to undergo pancreaticoduodenectomy are randomized before operation to either a conventional approach (arm A) or a mesenteric approach (arm B). In arm A, the operation starts with Kocher's maneuver. At the final step of the removal procedure, the connective tissues around the superior mesenteric artery are dissected. In arm B, the operation starts with dissection of the connective tissues around the superior mesenteric artery and ends with Kocher's maneuver. In total, 354 patients from 15 Japanese high-volume centers will be randomized. The primary endpoint is overall survival by intention-to-treat analysis. Secondary endpoints include intraoperative blood loss, R0 rate, and recurrence-free survival. DISCUSSION: If the MAPLE-PD trial shows the oncological benefits of the mesenteric approach for patients with pancreatic ductal adenocarcinoma, this procedure may become a standard approach to pancreaticoduodenectomy. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03317886 . Registered on 23 October 2017. University Hospital Medical Information Network Clinical Trials Registry, UMIN000029615 . Registered on 15 January 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hirono S, Kawai M, Okada KI, et al. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma. Trials. 2018. PMID: 30409152. doi:10.1186/s13063-018-3002-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。